Cancer drug resistance: an evolving paradigm
- PMID: 24060863
- DOI: 10.1038/nrc3599
Cancer drug resistance: an evolving paradigm
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Similar articles
-
Mechanisms of tumor cell resistance to the current targeted-therapy agents.Tumour Biol. 2016 Aug;37(8):10021-39. doi: 10.1007/s13277-016-5059-1. Epub 2016 May 7. Tumour Biol. 2016. PMID: 27155851 Review.
-
Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?Open Biol. 2012 May;2(5):120066. doi: 10.1098/rsob.120066. Open Biol. 2012. PMID: 22724067 Free PMC article. Review.
-
Insights into new mechanisms and models of cancer stem cell multidrug resistance.Semin Cancer Biol. 2020 Feb;60:166-180. doi: 10.1016/j.semcancer.2019.07.022. Epub 2019 Jul 29. Semin Cancer Biol. 2020. PMID: 31369817 Review.
-
Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.Stem Cells Transl Med. 2015 Sep;4(9):1028-32. doi: 10.5966/sctm.2015-0054. Epub 2015 Jul 1. Stem Cells Transl Med. 2015. PMID: 26136502 Free PMC article.
-
Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells.Br J Cancer. 2013 May 28;108(10):2005-12. doi: 10.1038/bjc.2013.188. Epub 2013 Apr 30. Br J Cancer. 2013. PMID: 23632480 Free PMC article.
Cited by
-
Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.Theranostics. 2020 Sep 2;10(24):11092-11109. doi: 10.7150/thno.44997. eCollection 2020. Theranostics. 2020. PMID: 33042272 Free PMC article.
-
Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer.Front Oncol. 2020 Aug 21;10:1397. doi: 10.3389/fonc.2020.01397. eCollection 2020. Front Oncol. 2020. PMID: 32974144 Free PMC article.
-
The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis.Front Oncol. 2021 Feb 24;11:629640. doi: 10.3389/fonc.2021.629640. eCollection 2021. Front Oncol. 2021. PMID: 33718207 Free PMC article.
-
Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance.Cells. 2020 Jun 11;9(6):1450. doi: 10.3390/cells9061450. Cells. 2020. PMID: 32545155 Free PMC article. Review.
-
Targeting cancer cell adhesion molecule, CD146, with low-dose gold nanorods and mild hyperthermia disrupts actin cytoskeleton and cancer cell migration.J Colloid Interface Sci. 2021 Nov;601:556-569. doi: 10.1016/j.jcis.2021.05.144. Epub 2021 May 26. J Colloid Interface Sci. 2021. PMID: 34090032 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources